We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed at $157.48 in the latest trading session, marking a +2.57% move from the prior day. This move outpaced the S&P 500's daily gain of 0.33%. At the same time, the Dow added 1.08%, and the tech-heavy Nasdaq gained 0.08%.
Shares of the HIV and hepatitis C drugmaker have appreciated by 3.97% over the course of the past month, outperforming the Medical sector's loss of 0.15%, and the S&P 500's gain of 1.41%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company is expected to report EPS of $2.16, down 12.55% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $7.81 billion, up 0.59% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.47 per share and a revenue of $30.76 billion, indicating changes of -105.77% and +4.47%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.52% upward. At present, Gilead Sciences boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Gilead Sciences (GILD - Free Report) closed at $157.48 in the latest trading session, marking a +2.57% move from the prior day. This move outpaced the S&P 500's daily gain of 0.33%. At the same time, the Dow added 1.08%, and the tech-heavy Nasdaq gained 0.08%.
Shares of the HIV and hepatitis C drugmaker have appreciated by 3.97% over the course of the past month, outperforming the Medical sector's loss of 0.15%, and the S&P 500's gain of 1.41%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company is expected to report EPS of $2.16, down 12.55% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $7.81 billion, up 0.59% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.47 per share and a revenue of $30.76 billion, indicating changes of -105.77% and +4.47%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.52% upward. At present, Gilead Sciences boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.